Goris M.L., Bretille J.
Skeletal scintigraphy for the diagnosis of malignant metastat
ic disease to the bones // Radiother. Oncol. — 1985. — V.3. — P. 319 329.
Gosfield E. 3d, Alavi A., Kneeland B.
Comparison of radionuclide bone scans and
magnetic resonance imaging in detecting spinal metastases [see comments] // J. Nucl.
Med. — 1993. — V.34(12). — P. 2191 2198.
Goss P.E., Winer E.P., Tannock I.F.,
è ñîàâò. North American Vorozole Study
Group. Randomized phase III trial comparing the new potent and selective third genera
tion aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced
breast cancer patients // J. Clin. Oncol. — 1999 V. 17. — P. 52 63.
Gottward G., Szakolezai L.
Die therapie von knochen metastases bein mammakarzi
nom // Strahlentherapie. — 1981. —¹ 12. — 157. — P. 801 807.
Gowen M., Wood D.D., Thrie E.J., McGuire M.K.B., Russell R.G.G.
An interleukin
1 like factor stimulates bone resorption in vitro // Nature. — 1983. —V. 306. —P. 378 380.
Gradishar W., Von Roenn J., Cobleigh M.,
è ñîàâò. A phase I study of marimastat
(MAR) in combination with Doxorubicin (A) and Cyclophosphamidi (C) in patients with
metastatic breast cancer (Abstract 476) // American Society of Clinical Oncology 35th
Annual Conference, Atlanta. — 1999.
Grant C.S., Hoare S.A., Millis R.R.
è ñîàâò. Urinary hydroxyproline and prognosis
in human breast cancer // Brit. J. Surg. — 1984. — V. 71(2). — P. 105 108.
Gregory E.J., Cohen S., Oines D.W., Mims C.H.
Megestrol acetate therary for
advanced breast cancer // J. Clin. Oncol. — 1985. — V.3. — P. 155 160.
Grill V., Ho P., Body J.J.
è ñîàâò. Parathyroid hormone related protein: Elevated
levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating
metastatic breast cancer // J.Clin. Endocrinol. Metab. — 1991. — V. 73. — P. 1309 1315.
Guerra U.P., Englaro E., Cattruzzi E
. Palliative therapy with rhenium 186
HEDP for bone metastases of breast cancer // Tumori. — 1997. — V. 83. — P. 560 562.
Guise T.A., Mundy G.R.
Breast cancer and bone // Curr. Opin. Endocrinol. —
1995. — V. 2. — P. 548 555.
Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., Yoneda T.,
Mundy G.R.
Evidence for a causal role of parathyroid hormone related protein in the
pathogenesis of human breast cancer mediated osteolysis // J. Clin. Invest. — 1996. —
V. 98(7). — P. 1544 1549.
Guise T.A., Mundy G.R.
Physiological and pathological roles of parathyroid hor
mone related peptide // Curr. Opin. Nephrol. Hypertens. — 1996. — V. 5(4). —
P. 307 315.
Guise T.A
. Parathyroid hormone related protein and bone metastases // Cancer. —
1997. — V. 80 (Suppl. 8). — P. 1572 1580.
Gurney H., Grill V., Martin T.J.
Parathyroid hormone related protein and response
to pamidronate in tumor induced hypercalcaemia // Lancet. — 1993. — V. 341. —
P. 1611 1613.
Haarstad H., Gundersen S., Wist E.,
è ñîàâò. Droloxifene: a new anti estrogen
Phase II study in advanced breast cancer // Acta Oncol. — 1992. — V. 31 — P. 425 428.
Hagel+Bradway S., Dziak R.
Regulation of bone cell metabolism // J. Oral Pathol.
Med. 1989. — V. 18. — P. 344 351.
Hahn P., Vikterlof K.S., Rydmari H
. è ñîàâò. The value of whole body scan in the
preoperative assessment of the breast cancer // Eur. J. Nucl. Med. — 1979. — V. 3. —
P. 207 21.
228
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
